AstraZeneca entices GSK R&D exec to head its Global Portfolio & Product Strategy

21 March 2013

Troubled Anglo-Swedish drug major AstraZeneca (LSE: AZN) announced that Marc Dunoyer is to join the company in the newly created role of executive vice president, Global Portfolio & Product Strategy. He will join the company in the second quarter of 2013, will report to chief executive Pascal Soriot and be a member of AstraZeneca’s senior executive team.

He will be responsible for driving business strategy, including business development, mergers and acquisitions, portfolio and product strategies. His most critical priorities will be to bolster the core growth platforms and therapy areas through well executed business development initiatives and leadership of internal efforts.

Mr Dunoyer will join AstraZeneca from UK pharma giant GlaxoSmithKline (LSE: GSK) where, as global head of rare diseases, he established an integrated global capability in treatments for rare diseases from R&D through to commercialization. He is also chairman of GSK Japan and a member of the corporate executive team. Previously at GSK he was president for Asia Pacific and Japan.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK